Showing 4151-4160 of 10903 results for "".
- Anzupgo Receives Positive CHMP Opinion for Adolescent CHEhttps://practicaldermatology.com/news/anzupgo-receives-positive-chmp-opinion-for-adolescent-che/2488490/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication for Anzupgo (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or i
- Report: Estimated 4.7 Million Americans Diagnosed With NMSC Annuallyhttps://practicaldermatology.com/news/report-estimated-47-million-americans-diagnosed-with-nmsc-annually/2488474/A new analysis from SkinCure Oncology estimates that 4.7 million Americans are diagnosed with nonmelanoma skin cancer (NMSC) each, approximately 42% higher than a commonly cited estimate based on 2012 data.
- Rubedo Plans Clinical Trial of RLS-1496 for Androgenetic Alopeciahttps://practicaldermatology.com/news/rubedo-plans-clinical-trial-of-rls-1496-for-androgenetic-alopecia/2488446/Rubedo Life Sciences announced plans to evaluate its investigational GPX4 modulator RLS-1496 in patients with androgenetic alopecia (AGA), following ex vivo findings showing increased growth of human hair follicles exposed to the agent, according to an a
- Meta-Analysis: IBD Events Are Rare With IL-17 Inhibitors in HShttps://practicaldermatology.com/news/meta-analysis-finds-rare-ibd-events-with-il-17-inhibitors-in-hs/2488443/Interleukin (IL)-17 inhibitors were not associated with a statistically significant increase in inflammatory bowel disease (IBD) risk among patients with hidradenitis suppurativa (HS) in a systematic review and meta-analysis published online in JAMA Dermatology. IBD Events Remain
- FDA Grants Priority Review to Zasocitinib for Plaque Psoriasishttps://practicaldermatology.com/news/fda-grants-priority-review-to-zasocitinib-for-plaque-psoriasis/2488421/The US Food and Drug Administration (FDA) has accepted Takeda’s new drug application (NDA) for zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis and granted the application Priority Review, according to a company announcement.
- Review Integrates Functional and Aesthetic BTX-A Treatment for Facial Paralysishttps://practicaldermatology.com/news/review-integrates-functional-and-aesthetic-btx-a-treatment-for-facial-paralysis/2488325/Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d BTX-A Targets Multiple Sequelae of Facial Paralysis The authors conduc
- Outpatient Dermatology Care Linked to Fewer HS Hospital Readmissions: Analysishttps://practicaldermatology.com/news/outpatient-dermatology-care-linked-to-fewer-hs-hospital-readmissions-analysis/2488266/Hidradenitis suppurativa (HS) carries a significant acute-care burden, but outpatient dermatology follow-up may be associated with fewer hospital readmissions, according to a study published in Archives of Dermatological Research
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://practicaldermatology.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Review Explores Energy-based Devices in Gender-affirming Carehttps://practicaldermatology.com/news/review-explores-energy-based-devices-in-gender-affirming-care/2488181/Laser and energy-based devices (EBDs) may address several dermatologic concerns relevant to transgender patients, from unwanted hair and acne to postoperative scars and body contouring, according to a recent review by Zarghami et al. Laser Applications Span Hair Removal, Acne, and Postsur
- Analysis: IBS Associated With 35% Higher Long-Term Risk of Psoriasishttps://practicaldermatology.com/news/analysis-ibs-associated-with-35-higher-long-term-risk-of-psoriasis/2488177/A large prospective cohort study showed a link between irritable bowel syndrome (IBS) and an elevated long-term risk of developing psoriasis compared to those without IBS.